Real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line (1L) axitinib + pembrolizumab therapy

First published 31/07/2024

Last updated 01/07/2025

EU PAS number:

EUPAS1000000104

Study

Finalised

Documents

Study protocol

Initial protocol

A4061101_NIS_Protocol_V2.0_10Jun2024_R.pdf

English (995.06 KB - PDF)View document

Updated protocol

A4061101_NIS_Protocol_V3.0_5March2025_Redacted.pdf

First published: 15/04/2025

English (433.1 KB - PDF)View document

Study results

Study report

A4061101 Study_Final_Report_v2_20250606_Redacted.pdf

English (1.62 MB - PDF)View document

Other information

Secondary tabs